Indeed, while in the major part of cancers low levels of ferroportin are related to poor prognosis [34, 35], in 2019 Gasparetto et al. observed an improved outcome to chemotherapy in AML expressing lower levels of ferroportin [14]. This evidence concerns the gene SLC40A1 and cancer.